Phuturdex › Diseases › Pancreatic neoplasm
Drugs in development · updated 30 October 2026
Pancreatic neoplasm: drugs in development
As of 30 October 2026 there are 416 active clinical trials (recruiting or ongoing, phases I–III) on 395 drugs for pancreatic neoplasm. 257 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials. Showing 40 of 257 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| GemcitabineGemcitabin, Gemzar | II–III | 108 | NCT06115499 |
| Nab-paclitaxelAbraxane, Nab-placlitaxel | II–III | 64 | NCT06361888 |
| IrinotecanOnivyde, CPT-11 | II–III | 28 | NCT02919787 |
| OxaliplatinOxaliplatine, Oxaliplain | II–III | 27 | NCT02919787 |
| Fluorouracil5-Fluorouracil, Adrucil | III | 26 | NCT07621718 |
| LeucovorinFolinic acid, l-leucovorin | III | 25 | NCT07621718 |
| CisplatinCis Platinum, Cisplatine | II–III | 15 | NCT06115499 |
| CapecitabineXeloda, Capectitabine Tablets | III | 12 | NCT06958328 |
| DaraxonrasibRasonque® | III | 8 | NCT07252232 |
| TislelizumabTisleizumab, Tiselizumab | III | 4 | NCT06332274 |
| TrastuzumabHerceptin, tratuzumab | II–III | 3 | NCT05786716 |
| PertuzumabPerjeta, Poherdy® | II–III | 2 | NCT05786716 |
| Ferric Carboxymaltose Injection [Ferinject]Injectafer® | III | 1 | NCT05744219 |
| LanreotideSomatuline Depot® | III | 1 | NCT06807437 |
| PanitumumabVectibix, Panitumumbab | III | 1 | NCT06998940 |
Sorted by most advanced phase and number of active trials. Showing 15 of 138 drugs.
All 395 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Islet cell adenoma 18 drugs
- Gastro-enteropancreatic neuroendocrine tumor 22 drugs
- Neuroendocrine tumor 84 drugs
- Pancreatic ductal carcinoma 23 drugs
- Somatostatinoma 8 drugs
- Colorectal neoplasm 534 drugs
- Neuroendocrine carcinoma 55 drugs
- Cholangiocarcinoma 136 drugs
- Carcinoid tumor 15 drugs
- Hypoglycemia 20 drugs
- Hyperinsulinism 14 drugs
- Non-small-cell lung carcinoma 726 drugs
Broader categories
- Digestive System Diseases 36 drugs
- Endocrine gland neoplasm 3 drugs
- Endocrine system disease 19 drugs
- Pancreatic Diseases 8 drugs
- Digestive system neoplasm 37 drugs
- Neoplasm 671 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D010190 “Pancreatic Neoplasms”.